CoChat

Unlicensed use of metformin in children and adolescents in the UK

Open access
Hsia, Yingfen, Dawoud, Dalia, Sutcliffe, Alastair G., Viner, Russell M., Kinra, Sanjay, Wong, Ian C. K. · 2012 · British Journal of Clinical Pharmacology
Cited by 44

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Metformin is licensed for type 2 diabetes mellitus (DM) treatment in the UK. • Evidence has shown the moderate efficacy of metformin treatment for polycystic ovarian syndrome (PCOS) and obesity. WHAT THIS STUDY ADDS • Metformin prescribing increased in children and adolescents between 2000 and 2010, in particular in girls aged 16–18 years. • PCOS and obesity were the main, but unlicensed, indications for metformin prescribing amongst female adolescents. AIM: Metformin is the most commonly prescribed oral anti‐diabetic drug in young people. It is also prescribed for polycystic ovarian syndrome (PCOS) and obesity treatment in adults in an unlicensed fashion. Little is known as to the extent metformin has been used in young people. We investigated the use of metformin in children and adolescents aged 0–18 years in the UK. METHODS: Population‐based prescribing data were obtained from the UK IMS Disease Analyzer between January 2000 and December 2010. RESULTS: A total of 2674 metformin prescriptions were issued to 337 patients (80% female) between 2000 and 2010. The prevalence of metformin prescribing increased from 0.03 per 1000 person‐years [95% confidence interval (CI) 0.02, 0.05] to 0.16 per 1000 person‐years (95% CI 0.12, 0.20) (P= 0.001). There was a steady increase in metformin prescribing in girls aged 16–18 years. There were 290 metformin treated patients (81% female; n= 235) who had at least one diagnosis of diabetes, PCOS or obesity. Among these patients, PCOS was the most common indication for metformin prescribing in girls (n= 120) followed by diabetes. There were 22 patients (7.6%) who received metformin for obesity treatment only. CONCLUSIONS: Prescribing of metformin increased between 2000 and 2010, in particular amongst girls aged 16–18 years. The main indication for metformin prescribing was PCOS. At present, metformin is not licensed for PCOS and obesity treatment in adults or children. As there is a steady increase in the prescribing of metformin in young people, further studies are required to investigate the efficacy and safety of these prescriptions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2011.04063.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Hsia, Y., Dawoud, D., Sutcliffe, A. G., Viner, R. M., Kinra, S., & Wong, I. C. K.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2011-12-08
Volume
73
Issue
1
Pages
135-139
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1487500578
Cited by
44
References
4
FWCI
2.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.